Search the Newsreel

Abbott India Q1 net profit surges 17% despite 4% revenue growth

Every 2 Seconds, Someone in the U.S. Needs Blood as Abbott Drive Returns

Abbott (NYSE: ABT) and the Big Ten Conference have relaunched their "We Give Blood" nationwide competition to address a critical blood supply crisis in the U.S. All 18 Big Ten universities will compete to generate the most blood donations, with Abbott awarding $1 million …

Abbott India Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

Abbott and Big Ten bring back 'We Give Blood' as U.S. faces blood supply crisis

"We Give Blood" brings together all 18 Big Ten® schools in a competition to drive the most blood donations and win $1 million from global healthcare company Abbott For only the second time in its history, the American Red Cross has declared a national …

Abbott Laboratories $ABT Shares Sold by West Branch Capital LLC

West Branch Capital LLC significantly reduced its stake in Abbott Laboratories (NYSE:ABT) by 83.5% in the second quarter, selling 13,061 shares and retaining 2,576 shares worth $234,000. Despite this sell-off, institutional investors collectively own 75.18% of Abbott’s stock. Abbott reported strong Q2 earnings of …

Butensky & Cohen Financial Security Inc. Purchases 9,277 Shares of Abbott Laboratories $ABT

Butensky & Cohen Financial Security Inc. increased its stake in Abbott Laboratories (NYSE:ABT) by 26.9% in the second quarter, acquiring an additional 9,277 shares to own a total of 43,809 shares valued at $3.98 million. This move comes as Abbott Laboratories reported strong quarterly …

Abbott Laboratories (NYSE:ABT) Receives Consensus Rating of "Moderate Buy" from Brokerages

Abbott Laboratories (NYSE:ABT) has received a consensus "Moderate Buy" rating from twenty-six brokerages, with an average 12-month price target of $118.17. The company recently exceeded quarterly expectations with adjusted EPS of $1.31 and revenue of $12.59 billion, and announced a quarterly dividend of $0.63 …

¿Puede Abbott Laboratories (ABT) Estar 8% Infravalorada Tras Mejorar Su Previsión Anual?

Abbott Laboratories (ABT) schedules NYSE sale of stock from vested awards

Abbott Laboratories (ABT) has filed a Form 144 indicating a planned sale of 5,850 common shares through UBS Financial Services on or after August 11, 2026, on the NYSE. The shares originate from vested restricted stock awards granted on February 27, 2026, totaling 1,960, …

Two July Hires Receive Options on 65,350 BridgeBio Shares

BridgeBio Oncology Therapeutics (NASDAQ: BBOT) announced it granted inducement equity awards on August 10, 2026, to two new employees hired in July 2026. These employees received non-qualified stock options for an aggregate of 65,350 shares of common stock at an exercise price of $9.28 …

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Oncology Therapeutics (BBOT) announced inducement grants of non-qualified stock options to two new employees hired in July 2026. These grants, totaling 65,350 shares at an exercise price of $9.28 per share, were made under BBOT’s 2025 Inducement Plan and approved in accordance with …

BridgeBio Oncology Therapeutics (NASDAQ: BBOT) doubles R&D spend, logs $98.6M loss

Abbott Partners With Google Health For AI-Powered Glucose Monitoring

Abbott has partnered with Google Health to integrate its Lingo continuous glucose monitor (CGM) data into the Google Health app, offering AI-driven recommendations for non-diabetic users. This collaboration aims to help users make better lifestyle choices and will involve a large-scale metabolic health study. …

Abbott to integrate Google’s AI health coach into wearable glucose monitoring tech

Abbott is partnering with Google to integrate Google's AI health coach into its Lingo wearable glucose monitoring technology. This collaboration aims to enhance the functionality of Abbott's continuous glucose monitoring system by providing users with AI-powered personalized health insights and coaching. The initiative was …

Por que as ações da Abbott Laboratories estão subindo hoje? - Investing.com Brasil

Why is Abbott Laboratories stock gaining today?

Abbott Laboratories stock rose 1.2% after announcing a multi-year collaboration with Google Health. This partnership will integrate glucose data from Abbott's Lingo biowearable continuous glucose monitor into the Google Health app, offering personalized health recommendations. The deal also includes a large-scale metabolic health study, …

Abbott and Google launch first-of-its-kind partnership to transform everyday health through glucose insights and AI

Abbott and Google Health have announced a multi-year partnership to integrate glucose insights from Abbott's Lingo biowearable with Google's AI and consumer technology. This collaboration aims to provide personalized metabolic insights through the Google Health app, helping users understand how daily behaviors affect their …

Abbott, Google to Study How Sleep and Activity Affect Glucose

Abbott has announced a multi-year partnership with Google Health to integrate insights from Abbott's Lingo continuous glucose monitor with Google's AI and consumer technology. This collaboration aims to provide personalized metabolic insights through the Google Health app, offering AI-powered guidance on nutrition, activity, sleep, …

Abbott Laboratories price shows more positive signals - Forecast today - 11-08-2026

Abbott Laboratories (ABT) is showing positive signals, with its stock trading above its 50-day Simple Moving Average and momentum indicators generating bullish signals. The outlook remains bullish as long as support at $102.90 holds, with a target resistance level at $114.00. This forecast suggests …

Handelsbanken Fonder AB Sells 444,592 Shares of Abbott Laboratories $ABT

Handelsbanken Fonder AB reduced its stake in Abbott Laboratories by 37.6% in the second quarter, selling 444,592 shares and retaining 736,804 shares valued at approximately $66.9 million. Abbott Laboratories reported strong quarterly results, exceeding analyst expectations with $12.59 billion in revenue and adjusted earnings …

Abbott India shares climb over 2% to Rs 28,120.00

Abbott Laboratories (ABT) Just Gave Investors Something To Think About

Abbott Laboratories (ABT) recently exceeded quarterly estimates and increased its annual profit forecast, driven by strong performance in cancer diagnostics and medical devices. The company's stock has shown a significant short-term rebound, up 28.77% over 90 days, despite being down over the past year. …

Abbott vs. Medtronic: Is Consistent Growth Better Than a Turnaround Story?

Abbott Laboratories (NYSE:ABT) and Medtronic (NYSE:MDT) are both prominent names in the Medtech space. Abbott Laboratories (NYSE:ABT) delivered strong fiscal Q2 2026 results, beating quarterly estimates and raising its annual profit forecast as robust demand for its cancer diagnostics and medical devices businesses helped …

Abbott Continues to Oppose Spinal Cord Stimulator Lawsuit MDL, Despite Mounting Claims

Abbott Laboratories is opposing the consolidation of spinal cord stimulator lawsuits into a multidistrict litigation (MDL), despite a growing number of claims alleging dangerous defects in its devices. While a similar MDL has already been established for Boston Scientific, Abbott argues that its cases …

Fluent Financial LLC Makes New $1.73 Million Investment in Abbott Laboratories $ABT

Vertrix Wealth Management LLC Invests $2.67 Million in Abbott Laboratories $ABT

Vertrix Wealth Management LLC initiated a new position in Abbott Laboratories (NYSE:ABT) during the second quarter, purchasing 29,377 shares valued at approximately $2.67 million. Institutional investors collectively own about 75.18% of the company. Abbott Laboratories reported strong quarterly earnings and revenue, beating estimates, and …

Abbott Laboratories (ABT) Stock Analysis: Exploring a 9.84% Potential Upside Amid Strong Revenue Growth

Abbott Laboratories Aktie: 410. Quartalsdividende am 17. August

Gradient Investments LLC Sells 126,411 Shares of Abbott Laboratories $ABT

Gradient Investments LLC reduced its stake in Abbott Laboratories (ABT) by 34.9% in Q2 2026, selling over 126,000 shares but still retaining a significant holding worth $21.4 million. Despite this sale, institutional investors collectively own 75.18% of ABT. The company recently exceeded quarterly earnings …

BridgeBio Oncology Therapeutics, Inc. Stock 12‑Month Price Target Cut to $24.89, Implies 167% Upside

BridgeBio Oncology Therapeutics, Inc. (BBOT) has seen its average 12-month price target cut slightly from $25.3 to $24.89 by 9 analysts. This new target still implies a significant 167% potential upside from its August 7th closing price. The consensus rating from 10 covering analysts …

Abbott Laboratories (ABT) Could Be 10% Undervalued On Its $1.35b Buyback Update

Abbott Laboratories (ABT) has completed a $1.35 billion share buyback, repurchasing over 14 million shares. Despite recent short-term gains, the company's shares are considered 9.5% undervalued, with a fair value estimated at $119.13 compared to its current price of $107.81. Growth drivers include expanding …

Análise e Previsão das Ações da Abbott Laboratories (ABT)

Avior Wealth Management LLC Lowers Stake in Abbott Laboratories $ABT

Avior Wealth Management LLC reduced its stake in Abbott Laboratories (NYSE:ABT) by 47.5% in the second quarter, selling 19,199 shares and retaining 21,257 shares valued at $1.93 million. Despite this, analysts maintain a "Moderate Buy" rating for Abbott with an average price target of …

AbbVie vs. Abbott Laboratories: Which Healthcare Stock Is a Better Buy in 2026?

Choosing between a high-yield pharmaceutical powerhouse and a diversified healthcare leader requires looking at growth and stability. You must decide whether AbbVie (NYSE:ABBV) or Abbott Laboratories (NYSE:ABT) better fits your 2026 investment strategy. AbbVie focuses on high-margin specialized drugs, while Abbott operates across medical …

How Abbott Laboratories (ABT) Affects Rotational Strategy Timing

This article analyzes Abbott Laboratories (ABT) through the lens of rotational strategy timing, utilizing AI models to generate trading strategies. It highlights mixed sentiment, no clear price positioning signal, and compelling upside potential due to the absence of resistance levels above the current price. …

51,393 Shares in Abbott Laboratories $ABT Purchased by St. Louis Financial Planners Asset Management LLC

St. Louis Financial Planners Asset Management LLC recently acquired 51,393 shares of Abbott Laboratories (NYSE:ABT) worth approximately $4.9 million, making it their 10th-largest holding. Institutional investors now own 75.18% of the company, which holds a "Moderate Buy" consensus rating from analysts despite some recent …